PALISADE BIO, INC. Research And Development Expense

• PALISADE BIO, INC. showed a decrease of -50.3% in Research And Development Expense from 2019 to 2020.
• This data is from PALISADE BIO, INC.'s annual report (Form 10-K), filed with the SEC on March 22, 2021.
• XBRL data for this metric is available from 2009 to 2020 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2010: $2.61 million | Q3 2010: $2.11 million | Q1 2011: $1.74 million | Q2 2011: $2.09 million | Q3 2011: $2.12 million | Q1 2012: $1.42 million | Q2 2012: $1.60 million | Q3 2012: $1.39 million | Q1 2013: $1.75 million | Q2 2013: $1.91 million | Q3 2013: $1.85 million | Q1 2014: $1.63 million | Q2 2014: $2.00 million | Q3 2014: $2.11 million | Q1 2015: $3.18 million | Q2 2015: $3.31 million | Q3 2015: $3.39 million | Q1 2016: $3.07 million | Q2 2016: $2.47 million | Q3 2016: $3.59 million | Q1 2017: $2.90 million | Q2 2017: $2.59 million | Q3 2017: $1.38 million | Q1 2018: $1.17 million | Q2 2018: $1.01 million | Q3 2018: $897.1 thousand | Q1 2019: $1.51 million | Q2 2019: $954.5 thousand | Q3 2019: $825.5 thousand | Q1 2020: $696.9 thousand | Q2 2020: $446.0 thousand | Q3 2020: $466.0 thousand | Q1 2021: $471.1 thousand.
• Over the full 12 years of available data (2009 to 2020), PALISADE BIO, INC.'s Research And Development Expense has declined by 62.3%.
• Historical annual values: Fiscal year 2020: $2.02 million | Fiscal year 2019: $4.06 million | Fiscal year 2018: $3.96 million | Fiscal year 2017: $8.10 million | Fiscal year 2016: $13.16 million | Fiscal year 2015: $12.64 million | Fiscal year 2014: $8.36 million | Fiscal year 2013: $7.29 million | Fiscal year 2012: $6.11 million | Fiscal year 2011: $7.35 million | Fiscal year 2010: $9.16 million | Fiscal year 2009: $5.35 million.
• Data sourced from SEC EDGAR public filings as of August 7, 2026.

Last verified: August 7, 2026